1. Home
  2. QSR vs UTHR Comparison

QSR vs UTHR Comparison

Compare QSR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Restaurant Brands International Inc.

QSR

Restaurant Brands International Inc.

HOLD

Current Price

$78.20

Market Cap

26.2B

Sector

N/A

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

BUY

Current Price

$515.45

Market Cap

23.1B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
QSR
UTHR
Founded
1954
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.2B
23.1B
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
QSR
UTHR
Price
$78.20
$515.45
Analyst Decision
Buy
Buy
Analyst Count
18
14
Target Price
$81.35
$567.57
AVG Volume (30 Days)
2.1M
451.2K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
3.30%
N/A
EPS Growth
N/A
13.07
EPS
2.42
13.07
Revenue
$9,434,000,000.00
$1,483,300,000.00
Revenue This Year
$5.34
$6.39
Revenue Next Year
$1.88
$14.18
P/E Ratio
$32.26
$40.39
Revenue Growth
12.23
2.38
52 Week Low
$61.33
$375.61
52 Week High
$81.96
$609.35

Technical Indicators

Market Signals
Indicator
QSR
UTHR
Relative Strength Index (RSI) 55.81 48.98
Support Level $71.21 $518.82
Resistance Level $79.53 $540.53
Average True Range (ATR) 1.55 12.30
MACD 0.17 1.68
Stochastic Oscillator 62.49 62.99

Price Performance

Historical Comparison
QSR
UTHR

About QSR Restaurant Brands International Inc.

Restaurant Brands generates about $47 billion in system sales across more than 33,000 restaurants in over 120 markets, making it one of the largest restaurant companies globally. Its banners include Burger King (7,025 stores), Tim Hortons (4,586), Popeyes (3,578), and Firehouse Subs (1,449), concentrated in the US and Canada, with these brands also comprising 16,403 franchised international locations as of year-end 2025. The firm primarily earns revenue from franchise and property fees, supply chain sales within the Tim Hortons segment, company-operated restaurants, and advertising royalties.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: